Trial NCT01078974

View at ClinicalTrials.gov 
Org. Study IDs: 10-007
Secondary IDs: PO-WM-PI-0005

Last trial update was posted on 2016-07-25

MeSH Interventions

Dexamethasone Pomalidomide Rituximab

MeSH Conditions

Waldenstrom Macroglobulinemia

Other Conditions

Waldenstrom's Macroglobulinemia

Stopping Reasons

Safety concerns (IgM Flare)

Limitations And Caveats

Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID